Is Pulmatrix Stock a Good Investment?

Pulmatrix Investment Advice

PULM

To provide specific investment advice or recommendations on Pulmatrix stock, we recommend investors consider the following general factors when evaluating Pulmatrix. This will help you to make an informed decision on whether to include Pulmatrix in one of your diversified portfolios:

Examine Pulmatrix's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
Research Pulmatrix's leadership team and their track record. Good management can help Pulmatrix navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Pulmatrix's business and its evolving consumer preferences.
Compare Pulmatrix's performance and market position to its competitors. Analyze how Pulmatrix is positioned in terms of product offerings, innovation, and market share.
Check if Pulmatrix pays a dividend and its dividend yield and payout ratio.
Review what financial analysts are saying about Pulmatrix's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.

It's important to note that investing in Pulmatrix stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pulmatrix is a good investment.

Sell

Buy

Strong Sell

We provide trade recommendations to complement the recent expert consensus on Pulmatrix. Our dynamic recommendation engine exercises a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Pulmatrix is not overpriced, please check all Pulmatrix fundamentals, including its revenue, cash flow from operations, current asset, as well as the relationship between the cash per share and beta . Given that Pulmatrix has a price to earning of (1.30) X, we recommend you to check out Pulmatrix market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.

Market Performance	Good	Details
Volatility	Very risky	Details
Hype Condition	Under hyped	Details
Current Valuation	Undervalued	Details
Odds Of Distress	Quite High	Details
Economic Sensitivity	Moves slightly opposite to the market	Details
Investor Sentiment	Impartial	Details
Analyst Consensus	Buy	Details
Financial Strenth (F Score)	Very Weak	Details
Financial Leverage	Not Rated	Details
Reporting Quality (M-Score)	Possible Manipulator	Details

Examine Pulmatrix Stock

Researching Pulmatrix's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was at this time reported as 4.93. The company recorded a loss per share of 2.64. Pulmatrix last dividend was issued on the 6th of February 2019. The entity had 1:20 split on the 1st of March 2022.

To determine if Pulmatrix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulmatrix's research are outlined below:

	Pulmatrix is way too risky over 90 days horizon
	Pulmatrix appears to be risky and price may revert if volatility continues
	Pulmatrix has high likelihood to experience some financial distress in the next 2 years
	The company reported the previous year's revenue of 7.3 M. Net Loss for the year was (14.12 M) with profit before overhead, payroll, taxes, and interest of 6.07 M.
	Pulmatrix currently holds about 42.91 M in cash with (15.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
	Pulmatrix has a very weak financial position based on the latest SEC disclosures
	Latest headline from gurufocus.com: SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates ROIC, BERY, PULM on Behalf of Shareholders

Pulmatrix Quarterly Accounts Payable

373,000

Pulmatrix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulmatrix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulmatrix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.

	4th of April 2024 Upcoming Quarterly Report	View
	10th of May 2024 Next Financial Report	View
	31st of December 2023 Next Fiscal Quarter End	View
	4th of April 2024 Next Fiscal Year End	View
	30th of September 2023 Last Quarter Report	View
	31st of December 2022 Last Financial Announcement	View

Earnings surprises can significantly impact Pulmatrix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pulmatrix's investors have experienced.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2018-05-11	2018-03-31	-0.19	-0.24	-0.05	26
2023-08-10	2023-06-30	-1.23	-1.04	0.19	15
2021-05-11	2021-03-31	-2	-1.8	0.2	10
2023-03-30	2022-12-31	-1.44	-1.14	0.3	20
2018-08-03	2018-06-30	-1.7	-1.3	0.4	23
2024-03-28	2023-12-31	-1.04	-0.57	0.47	45
2021-08-10	2021-06-30	-2	-1.4	0.6	30
2018-11-14	2018-09-30	-1.8	-1.0	0.8	44

Know Pulmatrix's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Pulmatrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmatrix backward and forwards among themselves. Pulmatrix's institutional investor refers to the entity that pools money to purchase Pulmatrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.

		Shares
Hanson Mcclain Inc	2024-09-30	3.0
Wells Fargo & Co	2024-06-30	0.0
Citigroup Inc	2024-06-30	0.0
Morgan Stanley - Brokerage Accounts	2024-06-30	0.0
Gradient Investments	2024-09-30	0.0
Renaissance Technologies Corp	2024-09-30	117.2 K
Blackrock Inc	2024-06-30	54.9 K
Vanguard Group Inc	2024-09-30	35.1 K
Geode Capital Management, Llc	2024-09-30	29.6 K
State Street Corp	2024-06-30	13.9 K
Citadel Advisors Llc	2024-09-30	10.3 K

Note, although Pulmatrix's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pulmatrix's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.81 M.

Market Cap

6.45 Million

Pulmatrix's profitablity analysis

	Last Reported	Projected for Next Year
Return On Tangible Assets	(0.42)	(0.44)
Return On Capital Employed	(0.49)	(0.52)
Return On Assets	(0.42)	(0.44)
Return On Equity	(0.78)	(0.82)

The company has Profit Margin (PM) of (0.95) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.8) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.8.

Determining Pulmatrix's profitability involves analyzing its financial statements and using various financial metrics to determine if Pulmatrix is a good buy. For example, gross profit margin measures Pulmatrix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulmatrix's profitability and make more informed investment decisions.

Evaluate Pulmatrix's management efficiency

Pulmatrix has return on total asset (ROA) of (0.2999) % which means that it has lost $0.2999 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5899) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Non Currrent Assets Other are very stable compared to the past year. As of the 30th of November 2024, Total Current Assets is likely to grow to about 22.2 M, while Non Current Assets Total are likely to drop about 8.2 M.

	Last Reported	Projected for Next Year
Book Value Per Share	4.93	4.68
Tangible Book Value Per Share	4.93	4.68
Enterprise Value Over EBITDA	0.27	0.29
Price Book Value Ratio	0.38	0.40
Enterprise Value Multiple	0.27	0.29
Price Fair Value	0.38	0.40
Enterprise Value	-3.6 M	-3.8 M

The decision-making processes within Pulmatrix are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.

Beta

0.988

Basic technical analysis of Pulmatrix Stock

As of the 30th of November, Pulmatrix holds the Coefficient Of Variation of 510.58, risk adjusted performance of 0.1591, and Semi Deviation of 3.56. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pulmatrix, as well as the relationship between them. Please check Pulmatrix standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Pulmatrix is priced some-what accurately, providing market reflects its current price of 6.64 per share. Given that Pulmatrix has jensen alpha of 2.4, we recommend you to check out Pulmatrix's recent market performance to make sure the company can sustain itself at a future point.

Pulmatrix's insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmatrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Siegert Michelle over a week ago Disposition of 25000 shares by Siegert Michelle of Pulmatrix at 1.06 subject to Rule 16b-3
		Cabell Christopher over a week ago Acquisition by Cabell Christopher of 22100 shares of Pulmatrix at 0.3701 subject to Rule 16b-3
		Gillis Steven over three months ago Acquisition by Gillis Steven of 111 shares of Pulmatrix at 110.0 subject to Rule 16b-3
		Gillis Steven over three months ago Disposition of 880 shares by Gillis Steven of Pulmatrix at 28.0 subject to Rule 16b-3
		Teofilo Raad over a year ago Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3

Pulmatrix's Outstanding Corporate Bonds

Pulmatrix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pulmatrix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pulmatrix bonds can be classified according to their maturity, which is the date when Pulmatrix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	Volcan Compania Minera Corp Bond USP98047AC08	View
	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	PulteGroup 6 percent Corp Bond US745867AT82	View
	PulteGroup 55 percent Corp Bond US745867AW12	View

View All Pulmatrix Corporate Bonds

Understand Pulmatrix's technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing Pulmatrix's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

	Risk Adjusted Performance	0.1591
	Market Risk Adjusted Performance	(3.01)
	Mean Deviation	5.69
	Semi Deviation	3.56
	Downside Deviation	4.78
	Coefficient Of Variation	510.58
	Standard Deviation	11.8
	Variance	139.18
	Information Ratio	0.1842
	Jensen Alpha	2.4
	Total Risk Alpha	0.3312
	Sortino Ratio	0.4544
	Treynor Ratio	(3.02)
	Maximum Drawdown	92.85
	Value At Risk	(4.79)
	Potential Upside	16.69
	Downside Variance	22.87
	Semi Variance	12.67
	Expected Short fall	(7.65)
	Skewness	4.16
	Kurtosis	22.06

	Risk Adjusted Performance	0.1591
	Market Risk Adjusted Performance	(3.01)
	Mean Deviation	5.69
	Semi Deviation	3.56
	Downside Deviation	4.78
	Coefficient Of Variation	510.58
	Standard Deviation	11.8
	Variance	139.18
	Information Ratio	0.1842
	Jensen Alpha	2.4
	Total Risk Alpha	0.3312
	Sortino Ratio	0.4544
	Treynor Ratio	(3.02)
	Maximum Drawdown	92.85
	Value At Risk	(4.79)
	Potential Upside	16.69
	Downside Variance	22.87
	Semi Variance	12.67
	Expected Short fall	(7.65)
	Skewness	4.16
	Kurtosis	22.06

Consider Pulmatrix's intraday indicators

Pulmatrix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pulmatrix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

	Accumulation Distribution	37010.34
	Daily Balance Of Power	(0.48)
	Rate Of Daily Change	0.9
	Day Median Price	7.06
	Day Typical Price	6.92
	Price Action Indicator	(0.77)
	Period Momentum Indicator	(0.70)
	Relative Strength Index	44.72

Pulmatrix Corporate Filings

8K	13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about	View Verify
	17th of May 2024 Other Reports	View Verify

Pulmatrix time-series forecasting models is one of many Pulmatrix's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pulmatrix's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Pulmatrix Stock media impact

Far too much social signal, news, headlines, and media speculation about Pulmatrix that are available to investors today. That information is available publicly through Pulmatrix media outlets and privately through word of mouth or via Pulmatrix internal channels. However, regardless of the origin, that massive amount of Pulmatrix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.

A primary focus of Pulmatrix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulmatrix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulmatrix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulmatrix alpha.

Pulmatrix Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulmatrix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.

Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pulmatrix Corporate Management

MBA CMA	Interim Officer	Profile
Alexander Klibanov	Founder	Profile
Margaret MD	Chief Officer	Profile
David JD	Advisor	Profile
Aidan Curran	VP Affairs	Profile

When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports: